CN116173142A - Edible and medicinal homologous formula with metabolism regulating function, medicament and preparation method - Google Patents

Edible and medicinal homologous formula with metabolism regulating function, medicament and preparation method Download PDF

Info

Publication number
CN116173142A
CN116173142A CN202211602628.XA CN202211602628A CN116173142A CN 116173142 A CN116173142 A CN 116173142A CN 202211602628 A CN202211602628 A CN 202211602628A CN 116173142 A CN116173142 A CN 116173142A
Authority
CN
China
Prior art keywords
mixture
parts
edible
homologous
constant temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211602628.XA
Other languages
Chinese (zh)
Inventor
郑涵
唐斌
王胜利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202211602628.XA priority Critical patent/CN116173142A/en
Publication of CN116173142A publication Critical patent/CN116173142A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967—Lilium, e.g. tiger lily or Easter lily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The application relates to the technical field of health-care foods, in particular to a food and medicine homologous formula with a metabolism regulating function, a medicament and a preparation method thereof; the edible and medicinal homologous formula comprises the following components: phytosterol ester, lactobacillus bifidus, stevioside, peach kernel, lily, zinc succinate, mixed vitamins and taurine; the edible and medicinal preparation is prepared from an edible and medicinal preparation formula; the method comprises the following steps: stirring and mixing peach kernel, lily, stevioside, zinc succinate, plant sterol ester and mixed vitamin at a first constant temperature, grinding and filtering to obtain a first mixture; adding lactobacillus bifidus and taurine into the first mixture, and then stirring and mixing at a second constant temperature to obtain a second mixture; drying the second mixture, and then cooling to obtain a composite medicament; through peach kernel, stevioside, lactobacillus bifidus, zinc succinate, phytosterol ester, mixed vitamins and lily, the nutrition metabolism in blood is regulated, and the vascular state is improved.

Description

Edible and medicinal homologous formula with metabolism regulating function, medicament and preparation method
Technical Field
The application relates to the technical field of health-care foods, in particular to a food and medicine homologous formula with a metabolism regulating function, a medicament and a preparation method.
Background
Along with the improvement of living standard, a plurality of people have the problem of hyperlipidemia at the present stage, and as the hyperlipidemia can cause the rise of blood pressure, the phenomenon of lipid precipitation in vascular endothelium can occur for patients suffering from hyperlipidemia for a long time, and atherosclerosis can be caused, the rise of blood pressure can be further induced, and only vascular endothelial injury can be caused; under the combined action of vascular endothelial injury and atherosclerosis, lumen stenosis can appear in blood vessels for a long time, and even vascular occlusion can be caused when serious, so that vascular tissues are increased, and hypertension can be further induced.
Therefore, patients suffering from hyperlipidemia and hypertension need to pay attention to low salt and low fat on diet on one hand, on the other hand, the patients need to frequently participate in physical exercise, and meanwhile, the drugs for reducing the blood fat and the blood pressure need to be regularly taken, but the measures only can relieve the symptoms of the hyperlipidemia and the hypertension, and can not adjust the disturbed nutrition metabolism in blood due to eutrophication; therefore, how to regulate the nutrition metabolism in blood to improve the vascular state is a technical problem to be solved in the present application.
Disclosure of Invention
The application provides a food and medicine homologous formula with a metabolism regulating function, a medicament and a preparation method, and aims to solve the technical problem that nutrition metabolism in blood is difficult to regulate in the prior art.
In a first aspect, the present application provides a food-drug homologous formula with a metabolic regulation function, comprising, in parts by weight:
phytosterol esters: 50-70 parts of lactobacillus bifidus: 7-13 parts of stevioside: 2-10 parts of peach kernel: 3-7 parts of lily: 3-7 parts of zinc succinate: 3-7 parts of mixed vitamins: 3-7 parts of taurine: 1 to 5 parts.
Optionally, the mixed vitamins include: natural vitamin E blend or a mixture of natural vitamin E blend with other vitamins.
Optionally, the plant sterol ester is extracted from canola.
Optionally, the plant sterol ester comprises a mixture of β -sitosterol, campesterol, and stigmasterol.
Optionally, the mixture accounts for 80% or more of the total weight of the plant sterol ester.
In a second aspect, the present application provides a pharmaceutical and food homologous agent with metabolism regulating function, which is prepared from the pharmaceutical and food homologous formula in the first aspect.
In a third aspect, the present application provides a method of preparing a medicament according to the second aspect, the method comprising:
stirring and mixing peach kernel, lily, stevioside, zinc succinate, plant sterol ester and mixed vitamin at a first constant temperature, grinding and filtering to obtain a first mixture;
adding lactobacillus bifidus and taurine into the first mixture, and then stirring and mixing at a second constant temperature to obtain a second mixture;
and drying the second mixture, and cooling to obtain the composite medicament.
Optionally, the temperature of the first constant-temperature stirring is 20-30 ℃, and the time of the first constant-temperature stirring is 50-70 min.
Optionally, the temperature of the second constant temperature stirring is 30-40 ℃, and the time of the second constant temperature stirring is 20-40 min.
Optionally, the particle size of the first mixture is less than or equal to 2mm.
Compared with the prior art, the technical scheme provided by the embodiment of the application has the following advantages:
according to the food and medicine homologous formula with the metabolism regulating function, blood flow can be increased by adopting peach kernel to promote blood circulation to remove blood stasis, so that blood pressure is reduced, absorption of lipid substances by a human body is promoted through taurine, cholesterol and triglyceride in blood can be reduced, propagation of flora in intestinal tracts of the human body is promoted through stevioside, the metabolism speed of the human body is improved, absorption of lipid substances by the human body can be accelerated, environment of vitamin B and vitamin K can be prepared by the human body through improving the environment of small intestine through bifidus lactobacillus, absorption of lipid substances by the human body is further improved, hormone level in the human body, especially insulin level used for digestion is regulated through zinc succinate, digestion stage of the human body can be effectively promoted, absorption of cholesterol by the human body is inhibited through phytosterol ester, degradation metabolism of cholesterol is promoted and biochemical synthesis of cholesterol is inhibited, cell protection of the human body can be improved through mixing vitamins, finally, the state of the human body is stabilized, stable absorption of the human body is ensured, absorption and metabolism of nutrient substances in the blood can be regulated, and further, the regulation of nutrient effects in blood is realized.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the invention and together with the description, serve to explain the principles of the invention.
In order to more clearly illustrate the embodiments of the invention or the technical solutions of the prior art, the drawings which are used in the description of the embodiments or the prior art will be briefly described, and it will be obvious to a person skilled in the art that other drawings can be obtained from these drawings without inventive effort.
Fig. 1 is a schematic flow chart of a method provided in an embodiment of the present application.
Detailed Description
For the purposes of making the objects, technical solutions and advantages of the embodiments of the present application more clear, the technical solutions of the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is apparent that the described embodiments are some embodiments of the present application, but not all embodiments. All other embodiments, which can be made by one of ordinary skill in the art without undue burden from the present disclosure, are within the scope of the present application based on the embodiments herein.
In one embodiment of the present application, a food and drug homologous formula with a metabolic regulation function is provided, and the food and drug homologous formula includes, in parts by weight:
phytosterol esters: 50-70 parts of lactobacillus bifidus: 7-13 parts of stevioside: 2-10 parts of peach kernel: 3-7 parts of lily: 3-7 parts of zinc succinate: 3-7 parts of mixed vitamins: 3-7 parts of taurine: 1 to 5 parts.
In the embodiment of the application, the weight part of the plant sterol ester is 50-70 parts, and the positive effects are that the plant sterol ester can inhibit the absorption of cholesterol by human body, promote the degradation metabolism of cholesterol, inhibit the biochemical synthesis of cholesterol, and have the functions of muscle proliferation and enhancing capillary circulation, so that the absorption of lipid substances by organisms can be effectively promoted; when the weight part value is larger than the end value of the range, the cost of the integral homologous formula is too high, and when the weight part value is smaller than the end value of the range, the content of the plant sterol ester is insufficient, the absorption of lipid substances by an organism cannot be effectively promoted, and further the nutrition metabolism in blood cannot be regulated.
The beneficial effects of the weight part of the bifidus lactobacillus being 7-13 parts are that the bifidus lactobacillus is a dominant strain in the symbiotic bacteria in the small intestine, can provide the good environment for the organism to manufacture vitamin B and vitamin K, and further promote the organism to regulate the nutrition metabolism in the blood; when the weight part is smaller than the minimum value of the end point of the range, the content of the Lactobacillus bifidus is insufficient, and the good environment for manufacturing vitamin B and vitamin K by the organism cannot be maintained.
The stevioside has the positive effects that 2-10 parts by weight of stevioside can promote the propagation and growth of beneficial bacteria in human intestinal tracts, and meanwhile, the stevioside also has a seasoning effect and is suitable for diabetics to eat; when the value of the mass fraction is larger than the maximum value of the endpoints of the range, excessive stevioside can be caused, the propagation and the growth of beneficial bacteria in the intestinal tract can be influenced, and when the value of the mass fraction is smaller than the minimum value of the endpoints of the range, the addition amount of the stevioside is insufficient, the propagation and the growth of the beneficial bacteria in the intestinal tract of a human body can not be effectively promoted, and the taste can not be regulated.
The peach kernel has the positive effects that the peach kernel has the characteristics of bitter and sweet taste and flat nature, returns to heart, liver and large intestine channels, has the effects of reducing blood fat and viscosity, can promote blood circulation to remove blood stasis, can increase blood flow, and can reduce the flow resistance of blood, thereby reducing the blood pressure of blood vessels; when the weight portion is smaller than the end point minimum value of the range, the peach kernel content is insufficient, the flow resistance of blood cannot be reduced, and the pressure of blood vessels cannot be reduced.
The lily has the positive effects of moistening lung, relieving cough, clearing heart fire, soothing nerves and solving insomnia and dreaminess, and the lily can harmonize various medicines and effectively stabilize metabolism of a human body, so that the regulation of nutrition metabolism in blood is ensured, and the vascular state is improved.
The zinc succinate has the positive effects of 3-7 parts by weight, and can participate in the synthesis of insulin, growth hormone, male hormone, female hormone and other hormones, and zinc is an essential element for organ regeneration, maintenance of normal operation of the prostate and male hormone, or is an essential substance for normal tissue operation, digestion and removal of blood toxins, and zinc succinate also has antiviral capability and plays an important role in an immune system, so that the zinc succinate can promote the digestive metabolic capability of a human body by promoting the synthesis of insulin, regulate the nutritional metabolism in blood and improve the vascular state.
The mixed vitamins with the weight portions of 3 to 7 have the positive effects of protecting organism cells from being poisoned by free radicals, improving lipid metabolism, preventing coronary heart disease and atherosclerosis, thus effectively regulating nutrient metabolism in blood and improving vascular state; when the weight portion is smaller than the end point maximum value of the range, the cost of the formula is increased, and when the weight portion is smaller than the end point minimum value of the range, the mixed vitamins cannot effectively regulate the nutrition metabolism in blood, so that the vascular state cannot be improved.
The taurine with the weight portions of 1 to 5 has the positive effects that the taurine has the functions of reducing blood fat, reducing viscosity, reducing blood sugar and promoting the absorption of lipid substances, can reduce the absorption of cholesterol and triglyceride by human bodies, has the effects of promoting bile flow, protecting liver, detoxifying, improving immunity, resisting fatigue, inhibiting platelet aggregation and reducing coagulation, and has the protection effect on cardiac muscle, so that the absorption of lipid substances by blood can be reduced, the nutrition metabolism in blood can be regulated, and the vascular state can be improved; when the weight part is smaller than the end minimum value of the range, the content of the taurine is insufficient, and the absorption of lipid substances by blood cannot be effectively reduced, so that the nutrition metabolism in the blood cannot be regulated.
In some alternative embodiments, the vitamin mix comprises: natural vitamin E blend or a mixture of natural vitamin E blend with other vitamins.
In the embodiment of the application, the limiting effect of the natural mixed vitamin E contained in the mixed vitamin is that the natural mixed vitamin E has the greatest protective effect on body cells, and meanwhile, the effects of improving blood circulation, protecting tissues, reducing cholesterol and preventing hypertension can be effectively achieved, so that the nutrition metabolism in blood can be effectively regulated.
In some alternative embodiments, the phytosterol ester is extracted from canola.
In some alternative embodiments, the plant sterol ester includes a mixture of β -sitosterol, campesterol, and stigmasterol.
In the embodiment of the application, the source and the components of the plant sterol ester are limited, so that the plant sterol ester can effectively promote the organism to absorb lipid substances, and further effectively regulate the nutrition metabolism in blood.
In some alternative embodiments, the mixture comprises greater than or equal to 80% by weight of the total plant sterol ester.
In the embodiment of the application, the positive effect that the mixture accounts for more than or equal to 80 percent of the total weight of the plant sterol ester is that the plant sterol ester can effectively promote the absorption of lipid substances by an organism, and further effectively regulate the nutrition metabolism in blood.
In one embodiment of the application, a food and drug homologous medicament with a metabolism regulating function is provided, wherein the food and drug homologous medicament is prepared from the food and drug homologous formula.
In one embodiment of the present application, as shown in fig. 1, there is provided a method for preparing a food and drug homologous agent having a metabolic regulation function, the method comprising:
s1, stirring and mixing peach kernels, lily, stevioside, zinc succinate, phytosterol ester and mixed vitamins at a first constant temperature, and grinding and filtering to obtain a first mixture;
s2, adding lactobacillus bifidus and taurine into the first mixture, and then stirring and mixing at a second constant temperature to obtain a second mixture;
s3, drying the second mixture, and cooling to obtain the composite medicament.
In some alternative embodiments, the temperature of the first constant temperature agitation is 20 ℃ to 30 ℃ and the time of the first constant temperature agitation is 50min to 70min.
In the embodiment of the application, the first constant-temperature stirring temperature is 20-30 ℃, and the positive effects are that in the temperature range, the stirring of peach kernels, lily, stevioside, zinc succinate, phytosterol ester and mixed vitamins can be ensured to be sufficient, and meanwhile, the activity of each substance is stable; when the temperature is larger or smaller than the end value of the range, the stirring temperature is unstable, and the activity of the materials is affected.
The first constant-temperature stirring time is 50-70 min, and the positive effects of the first constant-temperature stirring time are that the stirring of peach kernels, lily, stevioside, zinc succinate, plant sterol esters and mixed vitamins can be ensured to be sufficient in the value range of the first constant-temperature stirring time; when the time value is larger or smaller than the end value of the range, the stirring time is too long or insufficient, and the activity of the materials is affected.
In some alternative embodiments, the temperature of the second constant temperature agitation is between 30 ℃ and 40 ℃, and the time of the second constant temperature agitation is between 20 minutes and 40 minutes.
In the embodiment of the application, the temperature of the second constant-temperature stirring is 30-40 ℃, and the positive effects are that in the temperature range, the stirring of peach kernels, lily, stevioside, zinc succinate, plant sterol ester and mixed vitamins can be ensured to be sufficient, and meanwhile, the activity of each substance is stable; when the temperature is larger or smaller than the end value of the range, the stirring temperature is unstable, and the activity of the materials is affected.
The second constant temperature stirring time is 20 min-40 min, and the positive effects of the second constant temperature stirring time are that the stirring of peach kernel, lily, stevioside, zinc succinate, plant sterol ester and mixed vitamin can be ensured to be sufficient in the value range of the second constant temperature stirring time; when the time value is larger or smaller than the end value of the range, the stirring time is too long or insufficient, and the activity of the materials is affected.
In some alternative embodiments, the particle size of the first mixture is less than or equal to 2mm.
In this application embodiment, the particle diameter of first mixture is less than or equal to 2 mm's positive effect is in this particle diameter range, can guarantee that peach kernel, lily and stevioside are fully broken to guarantee that the active material among them can evenly distribute in first mixture, and then guarantee that the holistic drug effect of formula is stable.
Example 1
A food and medicine homologous formula with a metabolism regulating function comprises the following components in parts by weight:
phytosterol esters: 60 parts of Lactobacillus bifidus: 10 parts of stevioside: 8 parts of peach kernel: 5 parts of lily: 5 parts of zinc succinate: 5 parts of mixed vitamins: 5 parts of taurine: 2 parts.
The mixed vitamins include: natural vitamin E blend or a mixture of natural vitamin E blend with other vitamins.
The phytosterol ester is extracted from olive type rape.
The phytosterol esters include a mixture of beta-sitosterol, campesterol and stigmasterol.
The mixture accounts for more than or equal to 80 percent of the total weight of the plant sterol ester.
A medicinal preparation with metabolism regulating effect is prepared from medicinal and edible components
A method for preparing a food and drug homologous medicament with metabolic regulation function, comprising:
s1, stirring and mixing peach kernels, lily, stevioside, zinc succinate, phytosterol ester and mixed vitamins at a first constant temperature, and grinding and filtering to obtain a first mixture;
s2, adding lactobacillus bifidus and taurine into the first mixture, and then stirring and mixing at a second constant temperature to obtain a second mixture;
s3, drying the second mixture, and cooling to obtain the composite medicament.
The temperature of the first constant temperature stirring is 25 ℃, and the time of the first constant temperature stirring is 60min.
The temperature of the second constant temperature stirring is 37 ℃, and the time of the second constant temperature stirring is 30min.
The particle size of the first mixture is less than or equal to 2mm.
Example 2
Example 2 and example 1 were compared, and the difference between example 2 and example 1 is that:
the edible and medicinal homologous formula comprises the following components in parts by weight:
phytosterol esters: 50 parts of Lactobacillus bifidus: 7 parts of stevioside: 2 parts of peach kernel: 3 parts of lily: 3 parts of zinc succinate: 3 parts of mixed vitamins: 3 parts of taurine: 1 part.
The temperature of the first constant temperature stirring is 20 ℃, and the time of the first constant temperature stirring is 50min.
The temperature of the second constant temperature stirring is 30 ℃, and the time of the second constant temperature stirring is 20min.
The particle size of the first mixture is less than or equal to 2mm.
Example 3
Example 3 was compared with example 1, and the difference between example 3 and example 1 was:
the edible and medicinal homologous formula comprises the following components in parts by weight:
phytosterol esters: 70 parts of Lactobacillus bifidus: 13 parts of stevioside: 10 parts of peach kernel: 7 parts of lily: 7 parts of zinc succinate: 7 parts of mixed vitamins: 7 parts of taurine: 5 parts.
The temperature of the first constant temperature stirring is 30 ℃, and the time of the first constant temperature stirring is 70min.
The temperature of the second constant temperature stirring is 40 ℃, and the time of the second constant temperature stirring is 40min.
The particle size of the first mixture is less than or equal to 2mm.
Comparative example 1
Comparative example 1 was compared with example 1, and the difference between comparative example 1 and example 1 was that:
the edible and medicinal homologous formula only comprises phytosterol ester, lactobacillus bifidus, stevioside, peach kernel, zinc succinate and mixed vitamins.
Comparative example 2
Comparative example 2 and example 1 were compared, and the comparative example 2 and example 1 differ in that:
the edible and medicinal homologous formula only comprises phytosterol ester, lactobacillus bifidus, stevioside, peach kernel, zinc succinate and taurine.
Comparative example 3
Comparative example 3 was compared with example 1, and the difference between comparative example 3 and example 1 was that:
the edible and medicinal homologous formula only comprises phytosterol ester, lactobacillus bifidus, stevioside, peach kernel, mixed vitamins and taurine.
Comparative example 4
Comparative example 4 was compared with example 1, and the comparative example 4 and example 1 were different in that:
the edible and medicinal homologous formula only comprises phytosterol ester, lactobacillus bifidus, stevioside, zinc succinate, mixed vitamins and taurine.
Comparative example 5
Comparative example 5 was compared with example 1, and the difference between comparative example 5 and example 1 was that:
the edible and medicinal homologous formula only comprises phytosterol ester, lactobacillus bifidus, peach kernel, zinc succinate, mixed vitamins and taurine.
Comparative example 6
Comparative example 6 was compared with example 1, and the difference between comparative example 6 and example 1 was that:
the edible and medicinal homologous formula only comprises phytosterol ester, stevioside, peach kernel, zinc succinate, mixed vitamins and taurine.
Comparative example 7
Comparative example 7 was compared with example 1, and the comparative example 7 and example 1 were different in that:
the edible and medicinal homologous formula only comprises Lactobacillus bifidus, stevioside, semen Persicae, zinc succinate, mixed vitamins and taurine.
Related experiments:
in order to verify the effect of the edible and medicinal homologous formula, the application also provides an animal experiment related to the embodiment 1, which specifically comprises:
1. animal experiments-for detecting functionality:
1. experimental materials: 55 Dawley (SD) rats weighing about 160 g-180 g purchased from China food and drug inspection institute [ license number: SCXK (jing) 2009-0017].
2. The experimental object: edible and medicinal homologous formula and Simvastatin tablet (Simvastatin) (Hangzhou moesadong pharmaceutical Co., ltd.)
3. Experimental reagent:
total Cholesterol (TC) assay kit (available from the eastern European diagnostics products Co., ltd., zhejiang, lot number: 2011050040);
triglyceride (TG) assay kit (batch number 20110302, produced by Beijing North Huakangtai clinical reagent Co., ltd.);
low density lipoprotein (LDL-C) assay kit (manufactured by Beijing North China Kangtai clinical reagent Co., ltd., batch number: 20110312);
high density lipoprotein (HDL-C) assay kit (manufactured by Beijing North China Kangtai clinical reagent Co., ltd., batch number: 20110303);
free Fatty Acid (FFA) assay kit (Nanjing institute of biological engineering, lot number 20110730); the reagents described above were all commercially available in analytical purity.
4. Experimental instrument:
electronic balance (Beijing Sidoris balance Co., ltd., model BS 110S);
cryogenic centrifuge (KUBOTA corporation, model 5800);
high speed cryocentrifuge (Sigma type 1-15K);
a microplate reader (Thermo Electrom Corporation, model 1500);
ultraviolet visible spectrophotometer (Shanghai essence science and technology instruments Co., ltd., model 752).
5. The experimental method comprises the following steps:
(1) Manufacturing a hyperlipidemia model: the experimental rat hyperlipidemia model is established by adopting a high-fat feed feeding method, wherein 55 male SD rats are fed with common feed for 1 week, blood is taken from the retroorbital venous plexus after being fasted for 12 hours without water inhibition, serum is separated, the total serum cholesterol is determined according to a kit method, and is randomly divided into 5 groups according to the total cholesterol, namely a normal group, a model group, a food and medicine homologous formula low-dose group, a food and medicine homologous formula high-dose group and a simvastatin group, and 11 rats are fed in each group. Normal groups are fed with common feed, the other 4 groups are fed with high-fat feed (2% cholesterol, 0.5% pig bile salt, 10% lard, 0.2% propylthiouracil and 87.3% basic feed), blood is taken from the retroorbital venous plexus of the rat after continuous feeding for 6 weeks, the fasting TC level of the molding rat is measured, and the TC value of the rat is more than 7mmol/L, and the molding is considered successful.
(2) Detection of liver index: while feeding the high fat, the low dose group of the edible and medicinal homologous formula and the high dose group of the edible and medicinal homologous formula are respectively orally administered with 20g/kg and 40g/kg of edible and medicinal homologous formula according to the weight, the simvastatin group is administered with 15mg/kg of simvastatin, the model group and the normal group are administered with equal amount of distilled water for 6 weeks continuously, 1 time/d, on the 42 th day of administration, after the rats are fasted and not forbidden for 12 hours, the femoral artery is used for taking blood, the rats are killed after dislocation of cervical vertebrae, the rats are dissected, the liver is weighed, and the liver index is calculated.
(2) In vivo serological index: on days 14, 26 and 36 (after rats are fasted and water is not forbidden for 12 hours) after administration, blood is taken from the retroorbital venous plexus, serum is separated, TC is measured according to a kit method, on day 42 (after rats are fasted and water is not forbidden for 12 hours), femoral artery blood is taken, rats are killed after cervical dislocation, and TC, TG, FFA, HDL-C, LDL-C is measured from the separated serum.
6. Statistical method
All experimental data are expressed as mean ± standard deviation (x±s), and the differences are statistically significant as P <0.05 using t-test for group comparisons.
2. Analysis of results:
1. effects of edible and medicinal homologous formulas on liver index of hyperlipidemic rats:
compared with the normal group, the liver index of the rats in the model group is obviously increased (P < 0.01), and compared with the model group, the liver index of the rats in the edible and medicinal homologous formula low dose group, the edible and medicinal homologous formula high dose group and the simvastatin group is reduced, but the difference has no statistical significance, and the specific results are shown in Table 1.
TABLE 1
Group of Dosage (g/kg) Liver index (. Times.10) -2 )
Normal group - 2.72±0.02
Model group - 4.17±0.041
Low-dosage group of edible and medicinal homologous formula 20 3.74±0.03
Edible and medicinal homologous groupSquare high dose group 40 3.59±0.04
Simvastatin group 0.015 3.98±0.04
Note that: p <0.01 compared to the normal group.
2. Effect of edible and medicinal homologous formula on serum TC content of hyperlipidemic rats:
the serum Total Cholesterol (TC) content of the model group was significantly increased (P < 0.01) compared with the normal group, the serum TC content of the high dose group of the edible and medicinal homologous formula was significantly decreased (P < 0.01) on day 36 after administration compared with the model group, the serum TC of the low dose group of the edible and medicinal homologous formula and simvastatin group was also decreased (P < 0.05), and the serum TC detection result on day 42 was the same as that on day 36, and the specific results are shown in table 2.
TABLE 2
Figure BDA0003995828470000101
3. Effects of edible and medicinal homologous formulas on serum TG and FFA content of hyperlipidemic rats:
compared with the normal group, the contents of TG and FFA in the model group are obviously increased (P < 0.01), and compared with the model group, the contents of TG and FFA in the serum of the food-medicine homologous formula low-dose group, the serum of the food-medicine homologous formula high-dose group and the serum of simvastatin group are reduced (P <0.05, P < 0.01), so that the contents of triglyceride and free fatty acid in the serum of the rat with hyperlipidemia can be reduced by the food-medicine homologous formula low-dose group, the food-medicine homologous formula high-dose group and simvastatin, and the specific results are shown in Table 3.
TABLE 3 Table 3
Figure BDA0003995828470000102
4. Effects of edible and medicinal homologous formulas on serum lipoprotein content of hyperlipidemic rats:
compared with the normal group, the serum low density lipoprotein (LDL-C) content of the model group is obviously increased (P < 0.01), and the high density lipoprotein (HDL-C) content is obviously reduced (P < 0.05); compared with the model group, the serum LDL-C content of the low-dose group of the edible and medicinal homologous formula, the serum LDL-C content of the high-dose group of the edible and medicinal homologous formula and the serum HDL-C content of the simvastatin group are obviously reduced (P <0.05 and P < 0.01), and the specific results are shown in Table 4.
TABLE 4 Table 4
Figure BDA0003995828470000103
5. Summarizing:
hyperlipidemia has a number of index parameters, wherein, the rise of total cholesterol level in plasma is one of important factors of Atherosclerosis (AS), and the rise of TC, TG and LDL-C in plasma can promote the occurrence of atherosclerosis, so that the blood fat, in particular LDL-C, can delay or relieve the occurrence and the development of atherosclerosis, and HDL-C is a main carrier for transporting TC in extrahepatic tissues to the liver and is an anti-atherosclerosis lipoprotein, so that HDL-C deficiency and LDLC rise are one of important causes of hyperlipidemia and AS;
HDL-C mainly acts to accept cholesterol from extrahepatic tissues, convert the cholesterol into VLDL (very low density lipoprotein), transport the VLDL into the liver, remove TC from the liver to maintain TC metabolic balance, interfere lipid metabolism by lipid peroxidation in vivo, aggravate peroxidation by increased lipid deposition, provide enough reaction matrix for lipid peroxidation, inhibit FFA activity and increase consumption, and generate lipid peroxide end product MDA.
The experimental results show that the low dosage of the edible and medicinal homologous formula, the high dosage of the edible and medicinal homologous formula and simvastatin can obviously reduce the content of serum TC, TG and LDL-C of a hyperlipoidemia rat, improve the HDLC content, have the same effect as simvastatin, and the instant edible and medicinal homologous formula can obviously regulate lipid metabolism disorder, thereby being beneficial to resisting atherosclerosis.
Meanwhile, the low dosage of the edible and medicinal composition, the high dosage of the edible and medicinal composition and simvastatin can reduce the FFA content in serum, which indicates that the simvastatin can play a role in reducing blood fat and resisting atherosclerosis through the antioxidation.
Meanwhile, the drop rates of the respective indexes of the formulations of the examples and comparative examples compared with those of example 1 were counted, and the results are shown in table 5.
The statistical mode is as follows: the serum TC content, serum FFA content, low-density lipoprotein LDL-C and high-density lipoprotein HDL-C of each of the low-dose group and the high-dose group of the comparative example at 42d were counted with reference to the low-dose group of the edible-medicinal homologous formula and the high-dose group of the edible-medicinal homologous formula in example 1, respectively, and compared with the data of example 1, the degree of decrease in the data of each of the low-dose group and the high-dose group of the comparative example relative to the data of example 1 was counted, and the data of the low-dose group and the high-dose group were averaged, and the decrease rate of the serum TC content = [ (serum TC content of the high-dose group of example 1-serum TC content of a certain example high-dose group)/serum TC content of the high-dose group of example 1+ (serum TC content of the low-serum TC content of a certain example low-dose group)/serum TC content of the low-dose group of example 1 ]/2
TABLE 5
Figure BDA0003995828470000111
Figure BDA0003995828470000121
As can be seen from table 5:
by adopting the edible and medicinal homologous formula, the absorption and metabolism of organisms to nutrient substances in blood can be regulated through peach kernels, stevioside, lactobacillus bifidus, zinc succinate, phytosterol ester, mixed vitamins and lily, so that the regulation of nutrient metabolism in blood is realized, and the vascular state is improved.
One or more technical solutions in the embodiments of the present application at least further have the following technical effects or advantages:
(1) According to the edible and medicinal homologous formula, the absorption and metabolism of organisms to nutrient substances in blood can be regulated through peach kernels, stevioside, lactobacillus bifidus, zinc succinate, phytosterol esters, mixed vitamins and lily, so that the regulation of nutrient metabolism in blood is realized, and the vascular state is improved.
(2) According to the edible and medicinal homologous formula, as the Lactobacillus bifidus and the stevioside are adopted, not only can intestinal flora be regulated, the absorption of cholesterol by a human body be inhibited, the degradation metabolism of cholesterol and the biochemical synthesis of cholesterol be promoted, but also the taste of the whole formula can be regulated through the stevioside, and meanwhile, the plant sterol ester is adopted, the muscle proliferation can be promoted, and the capillary circulation can be enhanced, so that the systemic channels and a plurality of microcirculation reactions in the body can be opened, and meanwhile, the peach kernel, lily and taurine are adopted for protecting the cardiac muscle, the control of the cardiac muscle on blood can be regulated, the purposes of dissolving fat, discharging fat and softening and dredging the blood vessel can be achieved, the hardened plaque on the inner wall of the blood vessel can be fundamentally eliminated, the hypertension can be effectively regulated, the defect of arteriosclerosis caused by long-term use of a vasodilator can be overcome, the secretion of insulin by activating pancreatic B cells through zinc succinate is improved, the sensitivity of target cell receptors to insulin can be effectively reduced, and diabetes can be effectively reduced.
(3) The medicament provided by the embodiment of the application can effectively remove toxins in human bodies, resist oxidization and aging, reduce blood viscosity and improve human immunity.
(4) The medicament provided by the embodiment of the application can effectively improve occurrence of coronary heart disease, cerebral apoplexy, encephalatrophy and senile dementia, improve blood oxygen supply of heart, brain and kidney, and improve cerebral apoplexy sequela.
(5) The method provided by the embodiment of the application is simple and convenient to operate and easy and convenient to prepare.
It should be noted that in this document, relational terms such as "first" and "second" and the like are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Moreover, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising one … …" does not exclude the presence of other like elements in a process, method, article, or apparatus that comprises the element.
The endpoints and any values of the ranges disclosed herein are not limited to the precise range or value, and are understood to encompass values approaching those ranges or values. For numerical ranges, one or more new numerical ranges may be found between the endpoints of each range, between the endpoint of each range and the individual point value, and between the individual point value, in combination with each other, and are to be considered as specifically disclosed herein.
The foregoing is only a specific embodiment of the invention to enable those skilled in the art to understand or practice the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims (10)

1. The edible and medicinal homologous formula with the metabolism regulating function is characterized by comprising the following components in parts by weight:
phytosterol esters: 50-70 parts of lactobacillus bifidus: 7-13 parts of stevioside: 2-10 parts of peach kernel: 3-7 parts of lily: 3-7 parts of zinc succinate: 3-7 parts of mixed vitamins: 3-7 parts of taurine: 1 to 5 parts.
2. The edible and pharmaceutical homologous formulation according to claim 1, wherein the admixed vitamin comprises: natural vitamin E blend or a mixture of natural vitamin E blend with other vitamins.
3. The edible and pharmaceutical homologous formulation according to claim 1, wherein the phytosterol ester is extracted from canola.
4. A dietetic homologous formula according to claim 1 or 3, wherein the plant sterol ester comprises a mixture of β -sitosterol, campesterol and stigmasterol.
5. The edible and pharmaceutical homologous formulation according to claim 4, wherein the mixture comprises at least 80% by weight of the total plant sterol esters.
6. A food and drug homologous medicament with metabolism regulating function, wherein the food and drug homologous medicament is prepared from the food and drug homologous formula according to any one of claims 1 to 5.
7. A method of preparing the medicament of claim 6, comprising:
stirring and mixing peach kernel, lily, stevioside, zinc succinate, plant sterol ester and mixed vitamin at a first constant temperature, grinding and filtering to obtain a first mixture;
adding lactobacillus bifidus and taurine into the first mixture, and then stirring and mixing at a second constant temperature to obtain a second mixture;
and drying the second mixture, and cooling to obtain the composite medicament.
8. The method of claim 7, wherein the first constant temperature agitation is at a temperature of 20 ℃ to 30 ℃ and the first constant temperature agitation is for a time of 50min to 70min.
9. The method of claim 7, wherein the second constant temperature agitation is at a temperature of 30 ℃ to 40 ℃ and the second constant temperature agitation is for a time of 20min to 40min.
10. The method of claim 7, wherein the first mixture has a particle size of 2mm or less.
CN202211602628.XA 2022-12-13 2022-12-13 Edible and medicinal homologous formula with metabolism regulating function, medicament and preparation method Pending CN116173142A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211602628.XA CN116173142A (en) 2022-12-13 2022-12-13 Edible and medicinal homologous formula with metabolism regulating function, medicament and preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211602628.XA CN116173142A (en) 2022-12-13 2022-12-13 Edible and medicinal homologous formula with metabolism regulating function, medicament and preparation method

Publications (1)

Publication Number Publication Date
CN116173142A true CN116173142A (en) 2023-05-30

Family

ID=86445179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211602628.XA Pending CN116173142A (en) 2022-12-13 2022-12-13 Edible and medicinal homologous formula with metabolism regulating function, medicament and preparation method

Country Status (1)

Country Link
CN (1) CN116173142A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102047979A (en) * 2010-12-09 2011-05-11 江西美庐乳业有限公司 Phytosterol formula milk powder
CN103656150A (en) * 2013-09-17 2014-03-26 李则领 Life-cultivation and healthcare oral liquid and preparation method thereof
CN114617169A (en) * 2020-12-10 2022-06-14 湖南协和生物科技研究院有限公司 Milk powder for preventing and reducing hypertension, blood sugar and blood fat

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102047979A (en) * 2010-12-09 2011-05-11 江西美庐乳业有限公司 Phytosterol formula milk powder
CN103656150A (en) * 2013-09-17 2014-03-26 李则领 Life-cultivation and healthcare oral liquid and preparation method thereof
CN114617169A (en) * 2020-12-10 2022-06-14 湖南协和生物科技研究院有限公司 Milk powder for preventing and reducing hypertension, blood sugar and blood fat

Similar Documents

Publication Publication Date Title
RU2327463C2 (en) Medicinal agent and food substance or beverage for improved hyperglycemia
EP0342956A2 (en) Use of phytic acid or its salts for the treatment of hyperlipemia, obesity and obesity-related diseases
WO2011077800A1 (en) Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages
CN113546097B (en) Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia
US8394431B2 (en) Composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid
CN112168876A (en) Composition with blood fat reducing effect and preparation method and application thereof
CN107441217B (en) Oral emulsion rich in alpha-linolenic acid and preparation method thereof
WO2023005911A1 (en) Nucleotide composition for adjuvant treatment of diabetes, preparation method therefor, and use thereof
AU2008332981B2 (en) Use of phytoecdysones in the preparation of a composition for acting on metabolic syndrome
EP1644007B1 (en) Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes
CN112603953A (en) External composition for losing weight and reducing fat and preparation method thereof
Tharwat et al. Effectiveness of adding flaxseed to type 2 diabetic Patient’s regimen
CN116173142A (en) Edible and medicinal homologous formula with metabolism regulating function, medicament and preparation method
CN105558244A (en) Food assisting in reducing blood lipid, reducing blood sugar and improving immunity and preparation method of food
CN110269915A (en) A kind of Weight-reducing and lipid-lowering composition and preparation method thereof
CN108420890A (en) A kind of composition and preparation method thereof with effect for reducing blood fat
CN113143962B (en) A pharmaceutical composition for treating hyperlipidemia, and its preparation method
CN100559952C (en) Milk powder of a kind of reduction or maintenance blood sugar and preparation method thereof
CN101879162A (en) Weight-losing medicament formed by matching alpha-ricinoleic acid ethyl ester with berberine
CN108354080A (en) A kind of preparation method of obesity phase special weight-reducing dog grain
CN109999094B (en) Traditional Chinese medicine tea bag for treating hyperlipidemia
CN108159201A (en) A kind of product for adjusting Hyperlipemia population intestinal flora and preparation method and application
CN112691089B (en) Application of 1-phenyl-1-propanol in preparation of medicine for treating hyperlipidemia and/or diabetes
WO2005072757A1 (en) Imperatae rhizoma extract for treatment and prevention of obesity
CN109316565A (en) A kind of blood-fat reducing composition and its preparation method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination